MoonLake Immunotherapeutics (MLTX) Earnings Date, Estimates & Call Transcripts → Look Who Fired the World’s Richest Man (From Banyan Hill Publishing) (Ad) Free MLTX Stock Alerts $41.72 +0.01 (+0.02%) (As of 01:26 PM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateAug. 8EstimatedActual EPS (May. 12) -$0.22 Missed By -$0.03 Consensus EPS (May. 12) -$0.19 Latest SEC 10-Q Filing Get MoonLake Immunotherapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for MLTX and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueMLTX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.MLTX Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Banyan Hill PublishingThe World’s Richest Man Blindsided by AIThese billionaires know that early investors in AI stand to make a lot of money. The same is true for everyday Americans... including you.Get the full story here. MoonLake Immunotherapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242($0.30)($0.20)($0.25)Q2 20243($0.38)($0.23)($0.29)Q3 20243($0.55)($0.26)($0.37)Q4 20243($0.66)($0.27)($0.41)FY 202411($1.89)($0.96)($1.32)Q1 20251($0.71)($0.71)($0.71)Q2 20251($0.78)($0.78)($0.78)Q3 20251($0.69)($0.69)($0.69)Q4 20251($0.63)($0.63)($0.63)FY 20254($2.81)($2.81)($2.81)MLTX Earnings Date and InformationMoonLake Immunotherapeutics last posted its quarterly earnings data on May 12th, 2024. The reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.03. MoonLake Immunotherapeutics has generated ($0.75) earnings per share over the last year (($0.75) diluted earnings per share). Earnings for MoonLake Immunotherapeutics are expected to decrease in the coming year, from ($1.14) to ($1.63) per share. MoonLake Immunotherapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 8th, 2024 based off prior year's report dates.Read More MoonLake Immunotherapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/8/2024Estimated)------- 5/12/2024Q1 2024($0.19)($0.22)($0.03)($0.22)-- 2/29/2024Q4 2023($0.23)($0.12)+$0.11($0.12)--11/14/2023Q3 2023($0.23)($0.18)+$0.05($0.18)--8/10/2023Q2 2023($0.27)($0.23)+$0.04($0.23)-- 5/12/2023Q1 2023($0.28)($0.23)+$0.05($0.23)--3/20/2023Q4 2022($0.33)($0.31)+$0.02($0.31)-- Get the Latest News and Ratings for MLTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/14/2022Q3 2022($0.32)($0.27)+$0.05($0.27)--8/12/2022Q2 2022-($0.34)($0.34)($0.34)--5/16/2022Q1 2022-($0.18)($0.18)($0.18)-- MoonLake Immunotherapeutics Earnings - Frequently Asked Questions When is MoonLake Immunotherapeutics's earnings date? MoonLake Immunotherapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 8th, 2024 based off last year's report dates. Learn more on MLTX's earnings history. Did MoonLake Immunotherapeutics beat their earnings estimates last quarter? In the previous quarter, MoonLake Immunotherapeutics (NASDAQ:MLTX) missed the analysts' consensus estimate of ($0.19) by $0.03 with a reported earnings per share (EPS) of ($0.22). Learn more on analysts' earnings estimate vs. MLTX's actual earnings. How can I view MoonLake Immunotherapeutics's earnings report? MoonLake Immunotherapeutics's earnings report can be found in their filing with the SEC. View SEC filing How much profit does MoonLake Immunotherapeutics generate each year? MoonLake Immunotherapeutics (NASDAQ:MLTX) has a recorded net income of -$36.01 million. MLTX has generated -$0.75 earnings per share over the last four quarters. What is MoonLake Immunotherapeutics's EPS forecast for next year? MoonLake Immunotherapeutics's earnings are expected to decrease from ($1.14) per share to ($1.63) per share in the next year. More Earnings Resources from MarketBeat Related Companies: ACADIA Pharmaceuticals Earnings Bausch Health Companies Earnings Merus Earnings MorphoSys Earnings TG Therapeutics Earnings Corcept Therapeutics Earnings Amicus Therapeutics Earnings Arrowhead Pharmaceuticals Earnings Vera Therapeutics Earnings Indivior Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Home Depot: Earnings Mixed, Wait to Buy the DipTraders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution GE Aerospace is Ready for Liftoff After Strong Earnings This page (NASDAQ:MLTX) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldThis 1 Biotech Stock has been shocking the marketsHuge AlertsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsREAD THIS – If You Missed Out On The AI BoomBanyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
